{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:15:44Z","timestamp":1781374544491,"version":"3.54.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.neurol.2026.02.148","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:49:10Z","timestamp":1772714950000},"page":"493-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Calprotectin as an immune-dysregulation biomarker in amyotrophic lateral sclerosis: Insights for diagnosis and therapy"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0666-8665","authenticated-orcid":false,"given":"A.","family":"Mendon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4559-9170","authenticated-orcid":false,"given":"S.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4659-0026","authenticated-orcid":false,"given":"N.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7501-3170","authenticated-orcid":false,"given":"S.","family":"Bagwe Parab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2026.02.148_bib0540","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1212\/WNL.53.5.1123","article-title":"Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS Percutaneous Endoscopic Gastrostomy Study Group","volume":"53","author":"Chi\u00f2","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.02.148_bib0545","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000108917","article-title":"Amyotrophic lateral sclerosis in South-East England: a population-based study: the South-East England Register for Amyotrophic Lateral Sclerosis (SEALS Registry)","volume":"29","author":"Abhinav","year":"2007","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.neurol.2026.02.148_bib0550","unstructured":"ANG mutations segregate with familial and \u201csporadic\u201d amyotrophic lateral sclerosis | Nature Genetics [Internet]. [cited 2025 Feb 18]. https:\/\/www.nature.com\/articles\/ng1742. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0555","unstructured":"Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis - Ticozzi - 2011 - American Journal of Medical Genetics Part B: Neuropsychiatric Genetics - Wiley Online Library [Internet]. [cited 2025 Feb 18]. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajmg.b.31158. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0560","unstructured":"Genetics of familial amyotrophic lateral sclerosis | Neurology [Internet]. [cited 2025 Feb 18]. https:\/\/www.neurology.org\/doi\/10.1212\/01.wnl.0000296811.19811.db. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0565","doi-asserted-by":"crossref","unstructured":"Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues | Journal of Neurology, Neurosurgery & Psychiatry [Internet]. [cited 2025 Feb 17]. https:\/\/jnnp.bmj.com\/content\/79\/1\/6. Accessed 17 Feb 2025.","DOI":"10.1136\/jnnp.2006.104828"},{"key":"10.1016\/j.neurol.2026.02.148_bib0570","unstructured":"Incidence of amyotrophic lateral sclerosis in Europe | Journal of Neurology, Neurosurgery & Psychiatry [Internet]. [cited 2025 Feb 17]. https:\/\/jnnp.bmj.com\/content\/81\/4\/385. Accessed 17 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0575","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-510X(01)00611-6","article-title":"Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results","volume":"191","author":"Mazzini","year":"2001","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2026.02.148_bib0580","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/jnnp.2007.117788","article-title":"Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004","volume":"79","author":"O\u2019Toole","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2026.02.148_bib0585","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/(SICI)1097-4598(200003)23:3<336::AID-MUS4>3.0.CO;2-L","article-title":"Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot","volume":"23","author":"Goetz","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.neurol.2026.02.148_bib0590","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-4-3","article-title":"Amyotrophic lateral sclerosis","volume":"4","author":"Wijesekera","year":"2009","journal-title":"Orph J Rare Dis"},{"key":"10.1016\/j.neurol.2026.02.148_bib0595","doi-asserted-by":"crossref","first-page":"iv32","DOI":"10.1136\/jnnp.74.suppl_4.iv32","article-title":"The management of motor neurone disease","volume":"74","author":"Leigh","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"#cr-split#-10.1016\/j.neurol.2026.02.148_bib0600.1","unstructured":"The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. [cited 2025 Feb 18]"},{"key":"#cr-split#-10.1016\/j.neurol.2026.02.148_bib0600.2","unstructured":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1471-4159.2006.04346.x. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0605","doi-asserted-by":"crossref","first-page":"e00469","DOI":"10.1016\/j.neurot.2024.e00469","article-title":"Gut microbiota immune cross-talk in amyotrophic lateral sclerosis","volume":"21","author":"Kaul","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2026.02.148_bib0610","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrclinonc.2014.202","article-title":"Pragmatic issues in biomarker evaluation for targeted therapies in cancer","volume":"12","author":"de Gramont","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0615","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/cts.12865","article-title":"Fit-for-purpose biometric monitoring technologies: leveraging the laboratory biomarker experience","volume":"14","author":"Godfrey","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.neurol.2026.02.148_bib0620","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Atkinson Jr","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.neurol.2026.02.148_bib0625","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/cts.12865","article-title":"Fit-for-purpose biometric monitoring technologies: leveraging the laboratory biomarker experience","volume":"14","author":"Godfrey","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.neurol.2026.02.148_bib0630","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.neurol.2026.02.148_bib0635","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.neures.2023.09.002","article-title":"Protein biomarkers for the diagnosis and prognosis of amyotrophic lateral sclerosis","volume":"197","author":"Donini","year":"2023","journal-title":"Neurosci Res"},{"key":"10.1016\/j.neurol.2026.02.148_bib0640","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.slast.2022.07.003","article-title":"Inflammatory mediators, lipoproteins and apolipoproteins in early diagnosis of amyotrophic lateral sclerosis","volume":"27","author":"Alarcan","year":"2022","journal-title":"SLAS Technol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0645","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1136\/gutjnl-2021-324855","article-title":"Calprotectin: from biomarker to biological function","volume":"70","author":"Jukic","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.neurol.2026.02.148_bib0650","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jneuroim.2009.09.006","article-title":"Calprotectin levels in the cerebrospinal fluid reflect disease activity in multiple sclerosis","volume":"216","author":"Berg-Hansen","year":"2009","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0655","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0140-6736(90)93237-J","article-title":"Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin","volume":"336","author":"Steinbakk","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2026.02.148_bib0660","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/0888-7543(90)90027-R","article-title":"Related calcium-binding proteins map to the same subregion of chromosome 1q and to an extended region of synteny on mouse chromosome 3","volume":"8","author":"Dorin","year":"1990","journal-title":"Genomics"},{"key":"10.1016\/j.neurol.2026.02.148_bib0665","doi-asserted-by":"crossref","unstructured":"Expression pattern of two related cystic fibrosis-associated calcium-binding proteins in normal and abnormal tissues | Journal of Cell Science | The Company of Biologists [Internet]. [cited 2025 Feb 18]. https:\/\/journals.biologists.com\/jcs\/article-abstract\/91\/2\/221\/60223\/Expression-pattern-of-two-related-cystic-fibrosis?redirectedFrom=fulltext. Accessed 18 Feb 2025.","DOI":"10.1242\/jcs.91.2.221"},{"key":"10.1016\/j.neurol.2026.02.148_bib0670","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.4049\/jimmunol.164.9.4916","article-title":"IFN-\u03b3 and TNF regulate macrophage expression of the chemotactic S100 protein S100A81","volume":"164","author":"Xu","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0675","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood.V87.9.3919.bloodjournal8793919","article-title":"Induction of the chemotactic S100 protein, CP-10, in monocyte\/macrophages by lipopolysaccharide","volume":"87","author":"Hu","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2026.02.148_bib0680","unstructured":"Epidermal expression of the calcium binding surface antigen 27E10 in inflammatory skin diseases | Archives of Dermatological Research [Internet]. [cited 2025 Feb 18]. https:\/\/link.springer.com\/article\/10.1007\/BF00372067. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0685","unstructured":"Immunohistochemical Distribution and Serum Levels of the Ca2+ -Binding Proteins MRP8, MRP14 and Their Heterodimeric Form MRP8\/14 in Crohn's Disease | Digestion | Karger Publishers [Internet]. [cited 2025 Feb 18]. https:\/\/karger.com\/dig\/article-abstract\/56\/5\/406\/104371\/Immunohistochemical-Distribution-and-Serum-Levels?redirectedFrom=fulltext. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0690","unstructured":"Immunohistochemical demonstration of the calcium-binding proteins MRP8 and MRP14 and their heterodimer (27E10 antigen) in Crohn's disease - ScienceDirect [Internet]. [cited 2025 Feb 18]. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/0046817795900675?via%3Dihub. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0695","unstructured":"Robust shifts in S100a9 expression with aging: a novel mechanism for chronic inflammation | Scientific Reports [Internet]. [cited 2025 Feb 18]. https:\/\/www.nature.com\/articles\/srep01215. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0700","unstructured":"Calprotectin expression in human monocytes: induction by Porphyromonas gingivalis lipopolysaccharide, Tumor Necrosis Factor-\u03b1, and Interleukin-1\u03b2 - Suryono - 2005 - Journal of Periodontology - Wiley Online Library [Internet]. [cited 2025 Feb 18]. https:\/\/aap.onlinelibrary.wiley.com\/doi\/10.1902\/jop.2005.76.3.437. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0705","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3390\/biom12040519","article-title":"A structural perspective on calprotectin as a ligand of receptors mediating inflammation and potential drug target","volume":"12","author":"Garcia","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.neurol.2026.02.148_bib0710","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1189\/jlb.1012519","article-title":"RAGE regulation and signaling in inflammation and beyond","volume":"94","author":"Kierdorf","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0715","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2353\/ajpath.2006.050713","article-title":"Posttranslationally modified proteins as mediators of sustained intestinal inflammation","volume":"169","author":"Andrassy","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0720","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jmb.2006.04.009","article-title":"Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity","volume":"359","author":"Leukert","year":"2006","journal-title":"J Mol Biol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0725","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.str.2010.05.017","article-title":"Structural basis for ligand recognition and activation of RAGE","volume":"18","author":"Koch","year":"2010","journal-title":"Structure Elsev"},{"key":"10.1016\/j.neurol.2026.02.148_bib0730","unstructured":"Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications - Ramasamy - 2011 - Annals of the New York Academy of Sciences - Wiley Online Library [Internet]. [cited 2025 Feb 18]. https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2011.06320.x. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0735","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1038\/sj.emboj.7601805","article-title":"Structural and functional insights into RAGE activation by multimeric S100B","volume":"26","author":"Ostendorp","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.neurol.2026.02.148_bib0740","first-page":"519","article-title":"A Structural perspective on calprotectin as a ligand of receptors mediating inflammation and potential drug target. Biomolecules","volume":"12","author":"Garcia","year":"2022","journal-title":"Multidiscipl Dig Publ Inst"},{"key":"10.1016\/j.neurol.2026.02.148_bib0745","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1007\/s12035-020-02019-9","article-title":"Absence of receptor for advanced glycation end product (RAGE) reduces inflammation and extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis","volume":"57","author":"Lee","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0750","first-page":"212","article-title":"Study of ALS and RAGE using [11C]PBR28: mechanisms and therapeutic opportunities","volume":"61","author":"Wang","year":"2020","journal-title":"J Nucl Med Soc Nucl Med"},{"key":"10.1016\/j.neurol.2026.02.148_bib0755","unstructured":"Frontiers | Coevolution of the toll-like receptor 4 complex with calgranulins and lipopolysaccharide [Internet]. [cited 2025 Feb 18]. https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2018.00304\/full. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0760","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cyto.2008.01.006","article-title":"LPS\/TLR4 signal transduction pathway","volume":"42","author":"Lu","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.neurol.2026.02.148_bib0765","doi-asserted-by":"crossref","unstructured":"TLR4\/MyD88\/PI3K interactions regulate TLR4 signaling | Journal of Leukocyte Biology | Oxford Academic [Internet]. [cited 2025 Feb 18]. https:\/\/academic.oup.com\/jleukbio\/article-abstract\/85\/6\/966\/6975175?redirectedFrom=fulltext. Accessed 18 Feb 2025.","DOI":"10.1189\/jlb.1208763"},{"key":"10.1016\/j.neurol.2026.02.148_bib0770","unstructured":"The structural biology of toll-like receptors: structure [Internet]. [cited 2025 Feb 18]. https:\/\/www.cell.com\/structure\/fulltext\/S0969-2126(11)00072-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0969212611000724%3Fshowall%3Dtrue. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0775","unstructured":"JCI - Autoinhibitory regulation of S100A8\/S100A9 alarmin activity locally restricts sterile inflammation [Internet]. [cited 2025 Feb 18]. https:\/\/www.jci.org\/articles\/view\/89867. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0780","article-title":"The roles of toll-like receptor 4, CD33, CD68, CD69, or CD147\/EMMPRIN for monocyte activation by the DAMP S100A8\/S100A9","volume":"14","author":"M\u00f6ller","year":"2023","journal-title":"Front Immunol [Internet] Frontiers"},{"key":"10.1016\/j.neurol.2026.02.148_bib0785","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nri2056","article-title":"Siglecs and their roles in the immune system","volume":"7","author":"Crocker","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0790","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000492596","article-title":"CD33 in Alzheimer's disease\u2013biology, pathogenesis, and therapeutics: a mini-review","volume":"65","author":"Zhao","year":"2018","journal-title":"Gerontology"},{"key":"10.1016\/j.neurol.2026.02.148_bib0795","article-title":"The roles of toll-like receptor 4, CD33, CD68, CD69, or CD147\/EMMPRIN for monocyte activation by the DAMP S100A8\/S100A9","volume":"14","author":"M\u00f6ller","year":"2023","journal-title":"Front Immunol [Internet] Frontiers"},{"key":"10.1016\/j.neurol.2026.02.148_bib0800","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.3390\/biomedicines11112994","article-title":"Exploring the disease-associated microglia state in amyotrophic lateral sclerosis","volume":"11","author":"Jauregui","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.neurol.2026.02.148_bib0805","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/cvr\/cvab329","article-title":"Neutrophil extracellular traps: from physiology to pathology","volume":"118","author":"Hidalgo","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.neurol.2026.02.148_bib0810","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fimmu.2019.01000","article-title":"Regulation of toll-like receptor (TLR) signaling pathway by polyphenols in the treatment of age-linked neurodegenerative diseases: focus on TLR4 signaling","volume":"10","author":"Azam","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0815","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nn1876","article-title":"Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons","volume":"10","author":"Nagai","year":"2007","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.neurol.2026.02.148_bib0820","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.stem.2008.10.001","article-title":"Non-cell-autonomous effect of human SOD1G37R astrocytes on motor neurons derived from human embryonic stem cells","volume":"3","author":"Marchetto","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.neurol.2026.02.148_bib0825","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.stem.2008.09.017","article-title":"Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation","volume":"3","author":"Giorgio","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.neurol.2026.02.148_bib0830","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s13311-014-0329-3","article-title":"Protective and toxic neuroinflammation in amyotrophic lateral sclerosis","volume":"12","author":"Hooten","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neurol.2026.02.148_bib0835","article-title":"Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis","volume":"7","author":"Bowerman","year":"2013","journal-title":"Front Cell Neurosci [Internet] Frontiers"},{"key":"10.1016\/j.neurol.2026.02.148_bib0840","doi-asserted-by":"crossref","first-page":"17913","DOI":"10.1073\/pnas.0804610105","article-title":"T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS","volume":"105","author":"Chiu","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurol.2026.02.148_bib0845","unstructured":"CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS | PNAS [Internet]. [cited 2025 Feb 18]. https:\/\/www.pnas.org\/doi\/full\/10.1073\/pnas.0807419105. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0850","doi-asserted-by":"crossref","unstructured":"Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis | Brain | Oxford Academic [Internet]. [cited 2025 Feb 18]. https:\/\/academic.oup.com\/brain\/article\/134\/5\/1293\/286722. Accessed 18 Feb 2025.","DOI":"10.1093\/brain\/awr074"},{"key":"10.1016\/j.neurol.2026.02.148_bib0855","unstructured":"JCI - Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS [Internet]. [cited 2025 Feb 18]. https:\/\/www.jci.org\/articles\/view\/62636. Accessed 18 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0860","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00401-016-1548-y","article-title":"Peripheral monocytes are functionally altered and invade the CNS in ALS patients","volume":"132","author":"Zondler","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0865","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.slast.2022.07.003","article-title":"Inflammatory mediators, lipoproteins and apolipoproteins in early diagnosis of amyotrophic lateral sclerosis","volume":"27","author":"Alarcan","year":"2022","journal-title":"SLAS Technol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0870","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neurobiolaging.2021.01.015","article-title":"Deletion of the inflammatory S100-A9\/MRP14 protein does not influence survival in hSOD1G93A ALS mice","volume":"101","author":"Ribon","year":"2021","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurol.2026.02.148_bib0875","doi-asserted-by":"crossref","first-page":"689723","DOI":"10.3389\/fnins.2021.689723","article-title":"Serum and fecal markers of intestinal inflammation and intestinal barrier permeability are elevated in Parkinson's disease","volume":"15","author":"Dumitrescu","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1016\/j.neurol.2026.02.148_bib0880","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3390\/antiox11112201","article-title":"Microglial dysfunction in neurodegenerative diseases via RIPK1 and ROS","volume":"11","author":"Wu","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.neurol.2026.02.148_bib0885","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.expneurol.2012.06.011","article-title":"Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS","volume":"237","author":"Liao","year":"2012","journal-title":"Exp Neurol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0890","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1093\/brain\/awaa309","article-title":"The microglial component of amyotrophic lateral sclerosis","volume":"143","author":"Clarke","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.02.148_bib0895","doi-asserted-by":"crossref","first-page":"e39216","DOI":"10.1371\/journal.pone.0039216","article-title":"Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis","volume":"7","author":"Brettschneider","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2026.02.148_bib0900","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.4049\/jimmunol.181.7.4666","article-title":"Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells","volume":"181","author":"Sinha","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0905","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/neuonc\/now034","article-title":"Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8\/9 and arginase and suppress T cell function","volume":"18","author":"Gielen","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0910","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41380-023-01976-6","article-title":"The association between inflammatory markers in blood and cerebrospinal fluid: a systematic review and meta-analysis","volume":"28","author":"Gigase","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.neurol.2026.02.148_bib0915","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-170602","article-title":"CSF and plasma levels of inflammation differentially relate to CNS markers of Alzheimer's disease pathology and neuronal damage","volume":"62","author":"Bettcher","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurol.2026.02.148_bib0920","doi-asserted-by":"crossref","first-page":"155828","DOI":"10.1016\/j.cyto.2022.155828","article-title":"Interleukin-8: an evolving chemokine","volume":"153","author":"Matsushima","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.neurol.2026.02.148_bib0925","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.it.2004.11.002","article-title":"IL-7 and IL-15: therapeutic cytokines for immunodeficiency","volume":"26","author":"Alpdogan","year":"2005","journal-title":"Trends Immunol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0930","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa124","article-title":"Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune responses","volume":"2","author":"B\u00e9land","year":"2020","journal-title":"Brain Commun"},{"key":"10.1016\/j.neurol.2026.02.148_bib0935","doi-asserted-by":"crossref","first-page":"21362","DOI":"10.1074\/jbc.M600504200","article-title":"Tumor necrosis factor-\u03b1 induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner","volume":"281","author":"Takeuchi","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.neurol.2026.02.148_bib0940","doi-asserted-by":"crossref","first-page":"e28553","DOI":"10.1016\/j.heliyon.2024.e28553","article-title":"Serum cytokines profile changes in amyotrophic lateral sclerosis","volume":"10","author":"Xu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.neurol.2026.02.148_bib0945","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2007.10.028","article-title":"TNF and sTNFR1\/2 plasma levels in ALS patients","volume":"194","author":"Cereda","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0950","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/187152711794653751","article-title":"Targeting TNF-alpha to elucidate and ameliorate neuroinflammation in neurodegenerative diseases","volume":"10","author":"Frankola","year":"2011","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.neurol.2026.02.148_bib0955","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1038\/s41598-017-09097-1","article-title":"Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: a meta-analysis study","volume":"7","author":"Hu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2026.02.148_bib0960","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1212\/01.WNL.0000129913.44351.A3","article-title":"Low levels of the vascular endothelial growth factor in CSF from early ALS patients","volume":"62","author":"Devos","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.02.148_bib0965","unstructured":"Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort - Mariosa - 2017 - Annals of Neurology - Wiley Online Library [Internet]. [cited 2025 Feb 19]. https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.24936. Accessed 19 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0970","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3390\/cancers11081097","article-title":"Apolipoprotein A-I (ApoA-I), immunity, inflammation and cancer","volume":"11","author":"Georgila","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.neurol.2026.02.148_bib0975","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tem.2010.10.001","article-title":"High density lipoprotein: it's not just about lipid transport anymore","volume":"22","author":"Gordon","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.neurol.2026.02.148_bib0980","unstructured":"ALS risk reduced in people with higher density lipoprotein, Apolipoproteins [Internet]. Neurology live. 2021 [cited 2025 Aug 22]. https:\/\/www.neurologylive.com\/view\/als-risk-reduced-higher-density-lipoprotein-apolipoproteins. Accessed 22 Aug 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib0985","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/mds.26290","article-title":"Plasma ApoA1 associates with age at onset and motor severity in early Parkinson disease patients","volume":"30","author":"Swanson","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2026.02.148_bib0990","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fphar.2015.00278","article-title":"Importance of apolipoprotein A-I in multiple sclerosis","volume":"6","author":"Gardner","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurol.2026.02.148_bib0995","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/diagnostics11060984","article-title":"Association between serum concentrations of apolipoprotein A-I (ApoA-I) and Alzheimer's Disease: systematic review and meta-analysis","volume":"11","author":"Zuin","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.neurol.2026.02.148_bib1000","article-title":"Association of circulating apolipoprotein AI Levels in patients with Alzheimer's disease: a systematic review and meta-analysis","volume":"14","author":"Tong","year":"2022","journal-title":"Front Aging Neurosci [Internet] Frontiers"},{"key":"10.1016\/j.neurol.2026.02.148_bib1005","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/ana.24936","article-title":"Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort","volume":"81","author":"Mariosa","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.02.148_bib1010","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.78066","article-title":"Combination of serum neurofilament light chain and serum cardiac troponin T as biomarkers improves diagnostic accuracy in amyotrophic lateral sclerosis","volume":"99","author":"Lindenborn","year":"2026","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.02.148_bib1015","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1093\/brain\/awac394","article-title":"Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal","volume":"146","author":"Benatar","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2026.02.148_bib1020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1172\/JCI20682","article-title":"VEGF: a critical player in neurodegeneration","volume":"113","author":"Storkebaum","year":"2004","journal-title":"J Clin Invest Am Soc Clin Invest"},{"key":"10.1016\/j.neurol.2026.02.148_bib1025","unstructured":"Sargramostim (rhu GM-CSF) as cancer therapy (systematic review) and an immunomodulator. A drug before its time? - PMC [Internet]. [cited 2025 Feb 19]. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8416151\/. Accessed 19 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib1030","doi-asserted-by":"crossref","first-page":"e200019","DOI":"10.1212\/NXI.0000000000200019","article-title":"Combined regulatory T-lymphocyte and IL-2 treatment is safe, tolerable, and biologically active for 1 year in persons with amyotrophic lateral sclerosis","volume":"9","author":"Thonhoff","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurol.2026.02.148_bib1035","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3390\/ijms20040834","article-title":"Innate immune modulation by GM-CSF and IL-3 in health and disease","volume":"20","author":"Borriello","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.neurol.2026.02.148_bib1040","unstructured":"IFN\u03b3 protects motor neurons from oxidative stress via enhanced global protein synthesis in FUS-associated amyotrophic lateral sclerosis - Assoni - 2024 - Brain Pathology - Wiley Online Library [Internet]. [cited 2025 Feb 19]. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bpa.13206. Accessed 19 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib1045","unstructured":"The Therapeutic Potential of Metformin in ALS: Moving Through the ALSRP Pipeline from Therapeutic Development Award (TDA) to Pilot Clinical Trial Award (PCTA) [Internet]. [cited 2025 Feb 19]. https:\/\/cdmrp.health.mil\/alsrp\/research_highlights\/23Plowman_Ranum_Wymer_highlight.aspx. Accessed 19 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib1050","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/biomedicines9081000","article-title":"NAD+ precursors and antioxidants for the treatment of amyotrophic lateral sclerosis","volume":"9","author":"Obrador","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.neurol.2026.02.148_bib1055","unstructured":"Brain-Gut-Microbiota Axis in amyotrophic lateral sclerosis: a historical overview and future directions - PMC [Internet]. [cited 2025 Feb 19]. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10796086\/#sec13. Accessed 19 Feb 2025."},{"key":"10.1016\/j.neurol.2026.02.148_bib1060","first-page":"557","article-title":"Neutrophils in the focus: impact on neuroimmune dynamics and the gut\u2013brain axis. Gastrointestinal disorders","volume":"6","author":"Krsek","year":"2024","journal-title":"Multidiscipl Dig Publ Inst"},{"key":"10.1016\/j.neurol.2026.02.148_bib1065","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1111\/ejn.15422","article-title":"Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis","volume":"54","author":"Wright","year":"2021","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.neurol.2026.02.148_bib1070","unstructured":"Frontiers | New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022 [Internet]. [cited 2025 Feb 19]. https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2022.1054006\/full. Accessed 19 Feb 2025."}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378726004510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:41:35Z","timestamp":1781282495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378726004510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0035378726004510"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.02.148","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calprotectin as an immune-dysregulation biomarker in amyotrophic lateral sclerosis: Insights for diagnosis and therapy","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.02.148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}